These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26767544)

  • 21. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
    Bantis A; Grammaticos P
    Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
    Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
    Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
    Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
    Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical drivers for imaging testing in non-metastatic castration-resistant prostate cancer in clinical practice: Results of the IDENTIFICA study.
    Cózar Olmo JM; Carballido Rodríguez J; Rubio-Briones J; Useros Rodríguez E; Muñoz Del Toro J; García García-Porrero Á; Juárez-Soto Á;
    Actas Urol Esp (Engl Ed); 2021 Apr; 45(3):198-206. PubMed ID: 33558084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
    Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
    Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
    Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
    Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
    Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
    Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical metastases from prostate cancer: 10-year experience at a single institution.
    Vinjamoori AH; Jagannathan JP; Shinagare AB; Taplin ME; Oh WK; Van den Abbeele AD; Ramaiya NH
    AJR Am J Roentgenol; 2012 Aug; 199(2):367-72. PubMed ID: 22826398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
    Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
    Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a monoinstitutional experience.
    Colloca G; Venturino A; Addamo G; Ratti R; Coccorullo Z; Caltabiano G; Viale G; Guarneri D
    Urol Oncol; 2014 Jan; 32(1):42.e1-5. PubMed ID: 24239469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
    Tsumura H; Ishiyama H; Tabata KI; Sekiguchi A; Kawakami S; Satoh T; Kitano M; Iwamura M
    Prostate; 2019 Apr; 79(5):506-514. PubMed ID: 30585345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.